Although reporting an overall feasibility of RG7112-mediated inhibition of MDM2 and P53 activation in this type of tumor in vivo, the trial highlighted several clinical adverse events related to the drug treatment including hematological toxicity, making the long-term treatment with RG7112 a challenge [94]. This evidence concerns the gene TP53 and neoplasm.